Standard CXL better at stabilizing progressive keratoconus

Article

Benzalkonium chloride-assisted (BAC) transepithelial collagen crosslinking (CXL) with 0.5% proparacaine drops is less effective than standard CXL in patients with progressive keratoconus

Benzalkonium chloride-assisted (BAC) transepithelial collagen crosslinking (CXL) with 0.5% proparacaine drops is less effective than standard CXL in patients with progressive keratoconus, claims a study in the Journal of Cataract and Refractive Surgery.

The study, headed by Dr Carina Koppen, Department of Ophthalmology, Antwerp University Hospital, Belgium, enrolled 53 eyes of 38 keratoconus patients. The Placido disk device was used to measure sphere, cylinder, as well as maximum keratometry (K max) simulated K values and refractive power values.

Standard CXL was preceded by administration of proparacaine drops 0.5% preserved with BAC 0.005% every five minutes during a thirty minute time period. Results were compared before CXL and post-CXL at 6, 12 and 18 months.

Only corrected distance visual acuity demonstrated a statistically significant improvement at six and twelve months postoperatively. Standard CXL was significantly more effective in stabilizing progressive keratoconus.

Related Videos
Josefina Botta, MD, MSc, at ASCRS 2024
Dr Nir Shoham Hazon, Director, Miramichi EyeNB Centre of Excellence, New Brunswick, Canada
J. Morgan Micheletti, MD, speaks at the 2024 ASCRS meeting
Dr William Wiley of Cleveland Eye Clinic, Northeast Ohio
© 2024 MJH Life Sciences

All rights reserved.